NEW YORK – Infectious disease diagnostics company MeMed said on Tuesday that it has received the CE-IVD mark for its MeMed BV diagnostic test and its point-of-care MeMed Key platform.
With the clearance MeMed can begin offering the BV test at the point of care. The test measures a set of three host-response proteins to help distinguish between bacterial and viral infections and guide antibiotic use.
The company already offered a CE-IVD-marked ELISA version of the test.